ENTITY
Walvax Biotechnology Co A

Walvax Biotechnology Co A (300142 CH)

55
Analysis
Health Care • China
Walvax Biotechnology Company Limited develops, manufactures and sells bio-pharmaceutical vaccination products. The Company's products include haemophilus influenzae type b conjugate vaccine and meningococcal group A,C bivalent polysaccharide conjugate vaccine.
more
bullish•MSCI ACWI Index
•22 Nov 2019 05:57

Global Equity Strategy: Health Care Hitting On All Cylinders - Overweight

Global equities remain in a short-term consolidation phase, however we continue to believe the longer-term trend is up and to the right for the...

Logo
450 Views
Share
bullish•Quantitative Analysis
•15 Oct 2019 10:05

Shanghai/​​​Shenzhen Connect Flows: Midea, Luxshare, Walvax

In our weekly Shanghai/Shenzhen Connect Ideas series, we aim to help our investors understand the flow of northbound trades via the Shanghai and...

Logo
504 Views
Share
bullish•Kweichow Moutai
•23 May 2019 15:55

Shanghai/Shenzhen Connect Ideas: Technologies, Porks and Hard Liquors (2019-05-17)

In our weekly Shanghai/Shenzhen Connect Ideas series, we aim to help our investors understand the flow of northbound trades via the Shanghai and...

Logo
755 Views
Share
bullish•CanSino Biologics
•13 Mar 2019 14:58

CanSino Biologics (康希诺) IPO: Valuation Update (Part 3)

CanSino is a China-based biotechnology company with a focus on vaccine development. In our previous insight (link to Part 1 and Part 2), we have...

Logo
584 Views
Share
•04 Apr 2018 21:35

Attractive EM Charts

Emerging markets remain leadership. While many of the world's developed markets in correction or consolidation mode, EM markets continue to remain...

Logo
465 Views
Share
x